Evidence map›Paper›PMID 40272902›Full record

Trial reportRheumatology (Oxford, England)2025

Abatacept for the treatment of myositis-associated interstitial lung disease.

Rohit Aggarwal, Nantakarn Pongtarakulpanit, Daniel I Sullivan, Siamak Moghadam-Kia, Sangmee Sharon Bae, Jesse Wilkerson, Didem Saygin, Galina Marder, Swamy Venuturupalli, Paul F Dellaripa and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03215927 (A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03215927 phase2completednot on this map

A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome

TypeinterventionalSponsorRohit Aggarwal, MDRan2018 to 2023Enrolled20ConditionsMyositis, Interstitial Lung DiseaseArmsAbatacept, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Emerging therapies in idiopathic inflammatory myopathies.Journal of neuromuscular diseases · 2026
    Review
  4. Review
  5. Lung complications of Sjogren syndrome.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rohit AggarwalDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0001-7531-8038
Nantakarn PongtarakulpanitDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-1384-9834
Daniel I SullivanDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0001-5277-521X
Siamak Moghadam-KiaDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-0994-1590
Sangmee Sharon BaeDivision of Rheumatology, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.ORCID 0000-0002-7216-7219
Jesse WilkersonDLH, LLC, Bethesda, MD, USA.
Didem SayginDivision of Rheumatology, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0003-1675-597X
Galina MarderDepartment of Rheumatology, Northwell Health, Great Neck, NY, USA.ORCID 0000-0002-3625-1157
Swamy VenuturupalliDivision of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Beverly Hills, CA, USA.ORCID 0000-0003-0079-5109
Paul F DellaripaDepartment of Rheumatology, Brigham and Women's Hospital BWH, Boston, MA, USA.ORCID 0000-0003-0237-739X
Sonye K DanoffDivision of Pulmonary and Critical Care Medicine, Department of Medicine, John Hopkins Medicine, Baltimore, USA.ORCID 0000-0001-9172-8977
Tracy DoyleDivision of Pulmonary and Critical Care Medicine BWH, Brigham and Women's Hospital BWH, Boston, MA, USA.
Gary M HunninghakeDivision of Pulmonary and Critical Care Medicine BWH, Brigham and Women's Hospital BWH, Boston, MA, USA.ORCID 0000-0001-9782-2841
Joyce S LeeDepartment of Medicine, University of Colorado Denver, Aurora, CO, USA.ORCID 0000-0002-5758-8365
Aryeh FischerLung Fibrosis-Clinical Development Lead, Bristol Myers Squibb, Lawrenceville, NJ, USA.ORCID 0000-0003-2024-6780
Jeremy FalkDivision of Pulmonary and Critical Care, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-6892-0776
Cheilonda JohnsonDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-3040-4981
Diane KoontzDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Dana P AschermanDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-1387-0860
Chester V OddisDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-9529-3111

Funding

Clinical Genetics and Screening for Pulmonary FibrosisR01HL130974 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GARY MATTHEW HUNNINGHAKE, Benjamin Alexander Raby · 2016 to 2026
$10.0M
Genetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung AbnormalitiesR01HL135142 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO, GARY MATTHEW HUNNINGHAKE · 2017 to 2026
$7.7M
Interstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4M
Abatacept for the Treatment of Myositis-associated Interstitial Lung DiseaseBristol Myers SquibbGrant support for Investigator Initiated StudyNIH HHS R01 HL111024NIH HHS R01 HL130974NIH HHS R01 HL135142
6 · The paper itself

Abstract

objectivesThis randomized, placebo-controlled pilot trial evaluated the efficacy and safety of abatacept in patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD).

methodsParticipants with active ASyS-ILD were randomized to receive abatacept (n = 9) or placebo (n = 11) for 24 weeks, followed by a 24-week open-label extension with abatacept for all participants. The primary endpoint was a change in % predicted forced vital capacity (%FVC) from baseline to week 24. Secondary endpoints included changes in the FVC (ml), % predicted diffusing capacity of the lung for carbon monoxide (%DLCO), shortness of breath questionnaire (SOBQ) and pulmonary disease activity on a visual analogue scale (VAS) at weeks 24 and 48. Pre-post baseline analysis of FVC and quantitative image analysis (QIA) of high-resolution computed tomographic scans were performed. Data were analysed using a generalized linear mixed model. The study was not powered for primary or secondary endpoints.

resultsAt week 24, there was no significant difference in the primary endpoint of %FVC change between abatacept and placebo (between treatment difference of -0.35, 95%CI -6.91 to 6.21, P = 0.914) and in all secondary endpoints. However, by week 48, trends favouring abatacept in %FVC, FVC (ml), %DLCO and SOBQ were observed without statistical significance. There was a significant improvement in pulmonary disease activity VAS and pre-post baseline slopes of %FVC and QIA scores in the abatacept arm. Abatacept was generally well tolerated.

conclusionAbatacept did not significantly improve %FVC at 24 weeks. However, trends at 48 weeks suggest potential benefits, supporting the need for a larger, long-term randomized controlled trial. CLINICAL

trial registrationclinicaltrials.gov; NCT03215927.

Indexed as

AbataceptImmunosuppressive AgentsLung Diseases, InterstitialMyositisAdultAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedPilot ProjectsTomography, X-Ray ComputedTreatment OutcomeVital CapacityAbataceptImmunosuppressive Agentsabataceptanti-synthetase syndromeidiopathic inflammatory myopathyinterstitial lung diseaseplacebo-controlled trialrandomized

Identifiers

PMID40272902
PMCPMC12695049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.